Leveraging real-world evidence and observational studies in treating multiple sclerosis
A Aboseif, I Roos, S Krieger, T Kalincik… - Neurologic …, 2024 - neurologic.theclinics.com
In a rapidly evolving treatment landscape for multiple sclerosis (MS), the utilization of real-
world observational studies has become increasingly valuable for decisionmaking at the …
world observational studies has become increasingly valuable for decisionmaking at the …
Novel and Emerging Treatments to Target Pathophysiological Mechanisms in Various Phenotypes of Multiple Sclerosis
G Bsteh, A Dal Bianco, T Zrzavy, T Berger - Pharmacological Reviews, 2024 - ASPET
The objective is to comprehensively review novel pharmacotherapies used in multiple
sclerosis (MS) and the possibilities they may carry for therapeutic improvement. Specifically …
sclerosis (MS) and the possibilities they may carry for therapeutic improvement. Specifically …
Prognostic value of single-subject grey matter networks in early multiple sclerosis
The identification of prognostic markers in early multiple sclerosis (MS) is challenging and
requires reliable measures that robustly predict future disease trajectories. Ideally, such …
requires reliable measures that robustly predict future disease trajectories. Ideally, such …
Multiple sclerosis progression and relapse activity in children
P Iaffaldano, E Portaccio, G Lucisano, M Simone… - JAMA …, 2024 - jamanetwork.com
Importance Although up to 20% of patients with multiple sclerosis (MS) experience onset
before 18 years of age, it has been suggested that people with pediatric-onset MS (POMS) …
before 18 years of age, it has been suggested that people with pediatric-onset MS (POMS) …
The Patient‐Determined Disease Steps scale is not interchangeable with the Expanded Disease Status Scale in mild to moderate multiple sclerosis
Background and purpose The validity, reliability, and longitudinal performance of the Patient‐
Determined Disease Steps (PDDS) scale is unknown in people with multiple sclerosis (MS) …
Determined Disease Steps (PDDS) scale is unknown in people with multiple sclerosis (MS) …
The macular retinal ganglion cell layer as a biomarker for diagnosis and prognosis in multiple sclerosis: a deep learning approach
A Montolío, J Cegoñino, E Garcia‐Martin… - Acta …, 2024 - Wiley Online Library
Purpose The macular ganglion cell layer (mGCL) is a strong potential biomarker of axonal
degeneration in multiple sclerosis (MS). For this reason, this study aims to develop a …
degeneration in multiple sclerosis (MS). For this reason, this study aims to develop a …
Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple …
G Brittain, J Petrie, KEM Duffy, R Glover, K Hullock… - BMJ open, 2024 - bmjopen.bmj.com
Introduction Autologous haematopoietic stem cell transplantation (aHSCT) is increasingly
used as treatment for patients with active multiple sclerosis (MS), typically after failure of …
used as treatment for patients with active multiple sclerosis (MS), typically after failure of …
[HTML][HTML] Efficacy and safety of stem cell transplantation for multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials
Multiple sclerosis (MS) is a common autoimmune neurological disease affecting patients'
motor, sensory, and visual performance. Stem Cell Transplantation (SCT) is a medical …
motor, sensory, and visual performance. Stem Cell Transplantation (SCT) is a medical …
[HTML][HTML] Evaluation of machine learning-based classification of clinical impairment and prediction of clinical worsening in multiple sclerosis
Background Robust predictive models of clinical impairment and worsening in multiple
sclerosis (MS) are needed to identify patients at risk and optimize treatment strategies …
sclerosis (MS) are needed to identify patients at risk and optimize treatment strategies …
[HTML][HTML] Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study
CG Chisari, U Aguglia, MP Amato, R Bergamaschi… - …, 2024 - Elsevier
Abstract Treatment options for secondary progressive MS (SPMS) are limited, especially
considering that the new drugs recently approved are licensed for actively relapsing …
considering that the new drugs recently approved are licensed for actively relapsing …